Abediterol

Drug Profile

Abediterol

Alternative Names: AZD-0548; LAS 100977; OD LABA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.
  • Class Antiasthmatics; Bronchodilators
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Nov 2016 AstraZeneca completes a phase I trial for Asthma in Germany (NCT02777827)
  • 01 Nov 2016 AstraZeneca initiates a phase I trial for Chronic Obstructive Pulmonary Disease and Asthma (In voulnteers) in Germany (NCT02967159)
  • 01 Jun 2016 AstraZeneca initiates a phase I trial for Asthma in Germany (NCT02777827)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top